Andres Vargas Estrada, MD
Interventional Cardiology · Tallahassee, FLNPI 1760794192
Payments from drug & device makers
Across 299 payments — averaging $280.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procyrion, Inc.$59K
- Inari Medical, Inc.$6K
- Penumbra, Inc.$4K
- Boston Scientific$4K
- Abbott$2K
- Abiomed$2K
- plus $7K from 26 others
What the payments were for
- Travel & lodging$7,20636%
- Food & beverage$12,65764%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procyrion, Inc. | 2 | $59,371 |
| Inari Medical, Inc. | 12 | $5,838 |
| Penumbra, Inc. | 45 | $3,726 |
| Boston Scientific | 46 | $3,537 |
| Abbott | 25 | $2,193 |
| Abiomed | 20 | $1,928 |
| W. L. Gore & Associates, Inc. | 11 | $1,502 |
| Angiodynamics, Inc. | 26 | $1,341 |
| Medtronic(2 entities) | 39 | $1,204 |
| Limflow Inc. | 5 | $870 |
| Shockwave Medical, Inc | 21 | $641 |
| Veryan Medical Incorporated | 2 | $216 |
| Reflow Medical Inc | 2 | $200 |
| Boehringer Ingelheim | 4 | $169 |
| Stryker | 4 | $159 |
| Endologix LLC | 1 | $159 |
| Philips North America LLC | 6 | $156 |
| Cagent Vascular Inc | 2 | $147 |
| United Therapeutics Corporation | 1 | $117 |
| Amgen | 5 | $76 |
| Merck | 4 | $61 |
| E.r. Squibb & Sons, L.L.C. | 2 | $42 |
| Amarin Pharma, Inc. | 2 | $35 |
| Pfizer | 2 | $31 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $28 |
| Johnson & Johnson | 2 | $26 |
| AstraZeneca | 2 | $25 |
| Bayer | 1 | $24 |
| Avinger Inc. | 1 | $23 |
| Haemonetics Corporation | 1 | $20 |
| ZOLL Circulation Inc | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$2,935
- AngioJet Ultra 5000A$2,322
- Impella$1,545
- FLOWTRIEVER CATHETER, S$1,204
- EXCLUDER AAA Endoprosthesis$1,038
- LIMFLOW SYSTEM$998
- Omnilink Elite vascular stent system$932
- AngioVac$704
- CT THROMBECTOMY SYSTEM KIT$582
- Resolute$203
- OMNILINK ELITE$163
- ENDOCROSS Device$159
- Torus Stent Graft System$159
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$150
- Supera peripheral stent system$144
- CARDIOMEMS$133
- Auryon Laser System 100-120 Vac$131
- AMPLATZER AMULET$130
- AORTIX SYSTEM$126
- JARDIANCE$124
How this compares
$83,893 in reported general payments places this provider in the 80th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 119 | $91,101 |
| EliquisApixaban | 108 | $86,148 |
| EntrestoSacubitril/Valsartan | 64 | $53,558 |
| XareltoRivaroxaban | 58 | $46,464 |
| Repatha SureclickEvolocumab | 51 | $36,511 |
| Repatha SyringeEvolocumab | 31 | $27,791 |
| BrilintaTicagrelor | 35 | $23,607 |
| JardianceEmpagliflozin | 27 | $20,180 |
| Icosapent Ethyl | 23 | $10,868 |
| Praluent PenAlirocumab | 16 | $7,727 |
| DapagliflozinDapagliflozin Propanediol | 11 | $7,684 |
| Ranolazine ErRanolazine | 63 | $5,390 |
| Ezetimibe | 131 | $3,044 |
| Metoprolol Succinate | 180 | $2,587 |
| Atorvastatin Calcium | 217 | $2,267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $25 | $114,708154 claims |
| PfizerEliquis | $31 | $86,148108 claims |
| Johnson & JohnsonXarelto | $26 | $46,46458 claims |
| Boehringer IngelheimJardiance | $169 | $20,18027 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Tallahassee
- William DixonTallahassee$826K
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Roberto CubedduNaples$2M
- Arthur LeeGainesville$2M
- Ruby SatpathyJacksonville$1.8M
- Santhosh MathewsBradenton$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.